Stock comparison
Haemonetics
Phibro Animal Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
PAHC
Phibro Animal Health
Market cap
$1.35B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | PAHC | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 47D | HAE |
| Benjamin Graham | 85A | 80A | HAE |
| Philip Fisher | 60C | 31F | HAE |
| Peter Lynch | 54C | 35D | HAE |
| Joel Greenblatt | 31F | 44D | PAHC |
| Charlie Munger | 54D | 42D | HAE |
| Terry Smith | 55D | 38D | HAE |
Side-by-side metrics
| Metric | HAE | PAHC |
|---|---|---|
| Market cap | $2.98B | $1.35B |
| P/E (TTM) | 24.8x | 15.5x |
| EV/EBIT | 14.1x | 20.0x |
| ROIC (TTM) | 8.37% | 11.17% |
| Gross margin | 55.74% | 32.54% |
| Net margin | 7.29% | 6.35% |
| Revenue CAGR 5y | 7.65% | 11.68% |
| EPS CAGR 5y | 24.62% | -2.92% |
| Debt / Equity | 1.5x | 2.2x |
| Dividend yield | 0.0% | 1.32% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -2.92%+112%
- Market cap$2.98Bvs $1.35B+55%
- Gross margin55.74%vs 32.54%+42%
- Debt / Equity1.5xvs 2.2x+29%
PAHC leads on
- Dividend yield1.32%vs 0.0%+100%
- P/E (TTM)15.5xvs 24.8x+38%
- Revenue CAGR 5y11.68%vs 7.65%+34%
- ROIC (TTM)11.17%vs 8.37%+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.